VolitionRx Picks MBL to Distribute Nu.Q Discover in $1B Japan Diagnostics Market
VolitionRx has appointed Medical & Biological Laboratories Co. Ltd as non-exclusive distributor for its Nu.Q Discover assays in Japan, tapping into a market with nearly $1 billion accessible for companion diagnostics. The company’s assays serve close to 100 clients worldwide and showed substantial revenue growth in 2025.
1. Distributor Appointment
VolitionRx has named Medical & Biological Laboratories Co. Ltd as a non-exclusive distributor for its Nu.Q Discover assays in Japan, expanding its commercial network in the autoimmune and genetic diagnostics space.
2. Market Opportunity
Management estimates the Total Accessible Market for companion diagnostics at just under $1 billion, highlighting significant revenue potential in Japan’s diagnostics sector, particularly in autoimmune and oncology applications.
3. Global Client Base and 2025 Growth
The Nu.Q Discover pillar now serves nearly 100 clients worldwide, including top pharmaceutical and diagnostic firms, and delivered substantial revenue growth in 2025 driven by new clinical trial partnerships.
4. Outlook and Regulatory Pathway
VolitionRx expects to replicate 2025’s growth trajectory in 2026 and believes data generated through MBL’s distribution will support a future regulatory application for diagnostic approval in Japan.